TNF-α blockers, such as infliximab, adalimumab, certolizumab pegol, golimumab, and etanercept, have been approved for the treatment of rheumatoid arthritis and other immune-mediated diseases. The gene discussed is TNF; the disease is rheumatoid arthritis.